Skip to main content

Table 2 Meta-regression analysis for the associated factors and risk of amputation events in patients with SGLT2i treatment

From: SGLT2 inhibitors and lower limb complications: an updated meta‐analysis

Parameter β 95% CI P value Parameter β 95% CI P value
Demographic characteristic
 Age (year old) − 0.090 − 0.224, 0.045 0.163 Sex (male%) 0.013 − 0.023, 0.049 0.780
 BMI (kg/m2) 0.097 − 0.231, 0.426 0.506 Diabetes duration (year) 0.177 − 0.036, 0.390 0.984
HbA1c and weight change
 HbA1c change (%) 0.689 − 4.454, 5.832 0.761 Weight change (kg)* − 0.461 − 0.726, − 0.197 0.007
 HbA1c change difference (%) − 0.479 − 6.171, 5.213 0.848 Weight change difference (kg)* − 0.436 − 0.795, − 0.078 0.026
Hemodynamic indicator
 Baseline SBP (mmHg) 0.005 − 0.094, 0.105 0.902 Baseline DBP (mmHg)* − 0.528 − 0.852, − 0.205 0.009
 SBP change (mmHg) − 0.254 − 0.545, 0.037 0.075 DBP change (mmHg) − 0.279 − 0.638, 0.079 0.096
 Volume depletion (event%) − 0.372 − 0.900, 0.155 0.121
Renal function profile
 Baseline eGFR (mL/min/1.73m2) 0.058 − 0.393, 0.508 0.352 eGFR change (mL/min/1.73m2) 0.393 − 1.183, 1.969 0.550
PAD risk factor
 Previous PAD (%) 0.003 − 0.296, 0.301 0.973
  1. *P < 0.05. BMI body mass index, SGLT2i sodium glucose co-transporter 2 inhibitor, PAD peripheral arterial disease, SBP systolic blood pressure, DBP diastolic blood pressure, HCT hematocrit, eGFR estimated glomerular filtration rate